Finance

Stocks News Update: Veeva Systems Inc. (NYSE:VEEV) ; AbbVie Inc. (NYSE:ABBV)

Veeva Systems Inc. (NYSE:VEEV)

Veeva Systems Inc. operates as a provider of industry-specific, cloud-based software solutions for the life sciences industry. It offers enterprise applications, a multichannel platform, customer relationship management, and content management solutions. The Company provides its solutions to pharmaceutical, animal health, and biotechnology companies. Veeva Systems Inc. is headquartered in Pleasanton, California.

Veeva Systems Inc. (NYSE:VEEV)’s Financial Overview

Veeva Systems Inc. (NYSE) surged 0.69% yesterday to close its trading session at $87.53. The company has 1 year Price Target of $111.93. Veeva Systems Inc. has 52-Week high of $109.05 and 52-Week Low of $52.17. The stock touched its 52-Week High on 109.05 and 52-Week Low on 52.17. The stock traded with the volume of 1.32 Million shares yesterday. The firm shows the market capitalization of $12.87 Billion.

Veeva Systems Inc. (NYSE) reported its last quarterly earnings on 10/30/2018 where the firm reported its Actual EPS of $0.45/share against the analyst consensus estimate of $0.38/share. The difference between the actual and expected EPS is $0.07 a share with a surprise factor of 18.4%.

The firm is trading with SMA20 of -3.04 Percent, SMA50 of -3.23 Percent and SMA200 of 2.67 percent. Veeva Systems Inc. has P/S value of 15.8 while its P/B value stands at 11.14. Similarly, the company has Return on Assets of 14.5 percent, Return on Equity of 18.9 percent and Return on Investment of 14.8 Percent. The company shows Gross Margin and Operating Margin of 70.6 percent and 23.9 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 1.9 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 15 analysts offering 12-month price forecasts for Veeva Systems Inc have a median target of 112.00, with a high estimate of 125.00 and a low estimate of 92.00. The median estimate represents a +27.96% increase from the last price of 87.53.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

AbbVie Inc. (NYSE:ABBV)

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie aims to help patients’ live healthier lives and collaborate on sustainable healthcare solutions.

AbbVie Inc. (NYSE:ABBV)’s Financial Outlook

The 18 analysts offering 12-month price forecasts for AbbVie Inc have a median target of 96.50, with a high estimate of 135.00 and a low estimate of 71.00. The median estimate represents a +7.33% increase from the last price of 89.91.

AbbVie Inc. is estimated to report earnings on 01/25/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 8 analysts’ forecasts, the consensus EPS forecast for the quarter is $1.92. The reported EPS for the same quarter last year was $1.48.

According to Zacks Investment Research, AbbVie Inc. has a Consensus Recommendation of 2.33. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock surged 0.98% and closed its last trading session at $89.91. The company has the market capitalization of $136.47 Billion. The stock has 52-week high of $125.86 and 52-Week low of $77.5. The firm touched its 52-Week high on 125.86 and 52-Week low on 77.50. The company has volume of 7.07 Million shares. The company has a total of 1.52 Billion shares outstanding.

AbbVie Inc. (NYSE) in the last quarter reported its actual EPS of $2.14/share where the analyst estimated EPS was $2.02/share. The difference between the actual and Estimated EPS is $0.12. This shows a surprise factor of 5.9 percent.

The company has YTD performance of -7.03 percent. Beta for AbbVie Inc. stands at 1.46 while its ATR (average true range) is 3.24. The company has Weekly Volatility of 4.75%% and Monthly Volatility of 3.66%%.

AbbVie Inc. has distance from 20-day Simple Moving Average (SMA20) of 2.43%, Distance from 50-Day Simple Moving Average of 3.83 percent and Distance from 200-Day Simple Moving Average of -4.7%.

The Company currently has ROA (Return on Assets) of 11.2 percent, Return on Equity (ROE) of 0 Percent and Return on Investment (ROI) of 17.8% with Gross margin of 76.3 percent and Operating & Profit margin of 33% and 23.4% respectively.